US20110295187A1 - Fat Reduction Using External Laser Radiation and Niacin - Google Patents
Fat Reduction Using External Laser Radiation and Niacin Download PDFInfo
- Publication number
- US20110295187A1 US20110295187A1 US13/198,491 US201113198491A US2011295187A1 US 20110295187 A1 US20110295187 A1 US 20110295187A1 US 201113198491 A US201113198491 A US 201113198491A US 2011295187 A1 US2011295187 A1 US 2011295187A1
- Authority
- US
- United States
- Prior art keywords
- patient
- niacin
- fat
- laser energy
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F03—MACHINES OR ENGINES FOR LIQUIDS; WIND, SPRING, OR WEIGHT MOTORS; PRODUCING MECHANICAL POWER OR A REACTIVE PROPULSIVE THRUST, NOT OTHERWISE PROVIDED FOR
- F03B—MACHINES OR ENGINES FOR LIQUIDS
- F03B1/00—Engines of impulse type, i.e. turbines with jets of high-velocity liquid impinging on blades or like rotors, e.g. Pelton wheels; Parts or details peculiar thereto
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F03—MACHINES OR ENGINES FOR LIQUIDS; WIND, SPRING, OR WEIGHT MOTORS; PRODUCING MECHANICAL POWER OR A REACTIVE PROPULSIVE THRUST, NOT OTHERWISE PROVIDED FOR
- F03B—MACHINES OR ENGINES FOR LIQUIDS
- F03B13/00—Adaptations of machines or engines for special use; Combinations of machines or engines with driving or driven apparatus; Power stations or aggregates
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02K—DYNAMO-ELECTRIC MACHINES
- H02K7/00—Arrangements for handling mechanical energy structurally associated with dynamo-electric machines, e.g. structural association with mechanical driving motors or auxiliary dynamo-electric machines
- H02K7/18—Structural association of electric generators with mechanical driving motors, e.g. with turbines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00452—Skin
- A61B2018/00458—Deeper parts of the skin, e.g. treatment of vascular disorders or port wine stains
- A61B2018/00464—Subcutaneous fat, e.g. liposuction, lipolysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0644—Handheld applicators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/067—Radiation therapy using light using laser light
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F05—INDEXING SCHEMES RELATING TO ENGINES OR PUMPS IN VARIOUS SUBCLASSES OF CLASSES F01-F04
- F05B—INDEXING SCHEME RELATING TO WIND, SPRING, WEIGHT, INERTIA OR LIKE MOTORS, TO MACHINES OR ENGINES FOR LIQUIDS COVERED BY SUBCLASSES F03B, F03D AND F03G
- F05B2220/00—Application
- F05B2220/60—Application making use of surplus or waste energy
- F05B2220/602—Application making use of surplus or waste energy with energy recovery turbines
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F05—INDEXING SCHEMES RELATING TO ENGINES OR PUMPS IN VARIOUS SUBCLASSES OF CLASSES F01-F04
- F05B—INDEXING SCHEME RELATING TO WIND, SPRING, WEIGHT, INERTIA OR LIKE MOTORS, TO MACHINES OR ENGINES FOR LIQUIDS COVERED BY SUBCLASSES F03B, F03D AND F03G
- F05B2240/00—Components
- F05B2240/20—Rotors
- F05B2240/24—Rotors for turbines
- F05B2240/241—Rotors for turbines of impulse type
- F05B2240/2411—Pelton type
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02B—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO BUILDINGS, e.g. HOUSING, HOUSE APPLIANCES OR RELATED END-USER APPLICATIONS
- Y02B10/00—Integration of renewable energy sources in buildings
- Y02B10/50—Hydropower in dwellings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E10/00—Energy generation through renewable energy sources
- Y02E10/20—Hydro energy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49002—Electrical device making
- Y10T29/49009—Dynamoelectric machine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49229—Prime mover or fluid pump making
Definitions
- This invention relates to a method for non-invasive, non-traumatic shaping and contouring of a human body by external means.
- this invention relates to administering niacin to a patient to enhance the effects of applying laser energy to targeted external regions of a patient's body to reduce fat by facilitating the removal of the intracellular fat from fat cells in the targeted areas.
- liposuction wherein excess adipose tissue, also known as fat, is suctioned from the body of a patient.
- the typical purpose of the liposuction procedure is to leave the patient thinner, with aesthetically more appealing body contours. For example, liposuction is often performed on patients to remove excess fat in the abdominal, buttock, thigh, breast and arm regions of the body.
- Adipose tissue is made of adipocytes, or fat cells, which are enclosed membranes filled with globules of triglycerides. In normal fat the fat cells have regular contours and form into grapelike clusters. The intracellular fat is relatively fluid and, if the membrane is pierced, will flow out of the cell into the interstitial space.
- the interstitial space includes nerves, blood vessels, lymphatics and collagen fibers, among other substances.
- Liposuction is performed by inserting a narrow tube, or cannula, through a tiny incision in the skin into the subcutaneous fatty tissue.
- the cannula is repeatedly pushed then pulled through the fat layer, separating and puncturing the fat cells and suctioning them out.
- Suction action through the cannula is provided by a vacuum pump or a large syringe.
- the procedure carries with it some risks and side effects. Due to the physical damage induced, the procedure can damage nerves, lymphatics and vasculature in the surrounding area, often resulting in significant loss of blood as the blood is vacuumed out with the fat and the formation of seroma due to damaged lymphatic channels. In addition, the post-procedure recovery period is long and often accompanied by a great deal of inflammation, bruising and concomitant pain.
- a saline solution containing very dilute amounts of at least an anesthetic and a vasoconstrictor is injected subcutaneously into the area to be suctioned.
- the anesthetic reduces operative and post-operative pain and the vasoconstrictor helps reduce blood loss.
- Cannulas have been improved by enabling the cannula to emit laser light and ultrasound energy directly onto the fat cells.
- LLLT Low level laser therapy
- LLLT has been used increasingly in the treatment of a broad range of conditions such as treatment and repair of injured muscles and tendons.
- LLLT has improved wound healing, reduced edema, and relieved pain of various etiologies.
- LLLT has been used successfully post-operative to liposuction to reduce inflammation and pain. While a significant improvement over prior art, it is still invasive and carries with it the corresponding pain and risks.
- Non-invasive methods of fat reduction are preferred over invasive methods to minimize trauma to the patient, reduce the risk of infection, and speed up recovery time, among other reasons.
- topical agents have long been known which claim to reduce cellulite or at least the appearance of cellulite.
- Cellulite is a condition that gives the skin a rippled, dimpled appearance. The effect of these agents on cellulite is somewhat dubious, and these agents are not known to actually reduce fat.
- Some of the topical agents are used in combination with massage or radiation of the affected areas.
- U.S. Pat. No. 6,645,162 issued to Friedman, et al. discloses the superposition of ultrasound waves from two or more sources to create a wave having high intensity localized at the adipose tissue to be treated. With this method, fat cells are sonically disintegrated, allowing the body to dispose of the fat that has been freed. In addition to destruction of cells, another difficulty with this method is accurately obtaining the desired focal zone under the skin.
- an object of this invention is to provide a non-invasive method of reducing fat. Another object of this invention is to provide a non-invasive method of reducing cellulite. Another object is to provide a non-invasive method of reducing fat that does not destroy the fat cells, or damage surrounding tissue or structures. Another object is reduce fat using niacin to enhance the effects of low-level laser therapy. It is another object to eliminate the need for recovery time.
- the present invention is a non-invasive method for reducing fat or cellulite in a patient by administering a therapeutically effective amount of niacin and applying laser energy to targeted external regions of a patient's body.
- the present method helps create smooth contours.
- FIG. 1 is a schematic illustration of application of low-level laser radiation.
- FIG. 2 is a schematic illustration of normal fat cells.
- FIG. 3 is schematic illustration of fat cells after externally-applied low-level laser radiation.
- Niacin is a water-soluble vitamin necessary for many aspects of health, growth, and reproduction. It is part of the vitamin B complex, and is also known as nicotinic acid or vitamin B-3. Niacin assists in the functioning of the digestive system, skin, and nerves. It is also important for the conversion of food to energy. Niacin is found in dairy products, poultry, fish, lean meats, nuts, and eggs. Legumes and enriched breads and cereals also supply some niacin.
- Niacin can be administered orally, topically, sublingually, nasally, intravenously or otherwise parenterally.
- a therapeutic amount of niacin is the amount that increases the amount of fat metabolized by the patient's body.
- the therapeutically effective amount of niacin administered orally can be about 500 mg or more than about 15 mg.
- the therapeutically effective amount of niacin administered topically can be about 7 g.
- niacin is administered in a therapeutic amount orally, by tablet or liquid.
- Niacin is administered to the patient over a span of about two weeks. About 500 mg is taken per day during the first day and increased until the patient is taking about 1500 mg per day on the eleventh day.
- the patient is given 500 mg the first day in a single dose, and 100 mg is added each day to the dose until the patient is taking 1500 mg per dose. While most patients can tolerate relatively high doses of niacin, for example up to 3 grams a day, even smaller doses than those of the preferred embodiment can be associated with skin flushing and itching. It is desirable to keep the dose low enough to prevent the patient from being uncomfortable.
- the amount of niacin that is well-tolerated will differ for each patient. Similarly, the effect of the niacin and laser therapy will differ for each patient.
- the total amount of niacin administered, dose, timing and length of administration will vary for each patient, depending on the patient's tolerance, weight, body fat mass, and lean body mass, among other factors.
- niacin is administered topically to the patient in a therapeutic amount over a span of about two weeks. In a preferred embodiment, 7 grams of niacin is applied daily to the desired area.
- the niacin is carried in a lotion.
- a 20% niacin formulation is composed of Nia-112, commonly known as dodecyl nicotinate and nicotinic acid dodecyl ester included in a mixture of conventional ingredients found in a water- or lipid-soluble base.
- One such lotion comprises a nonionic surfactant such as Brij 58 (polyoxyethylene 20 cetyl ether), cetostearyl alcohol, glyceryl monostearate, polyethylene glycol 400 monostearate, propylene glycol, sorbitol (70%), petrolatum, sorbic acid, simethicone, and butylated hydroxytoluene.
- a nonionic surfactant such as Brij 58 (polyoxyethylene 20 cetyl ether), cetostearyl alcohol, glyceryl monostearate, polyethylene glycol 400 monostearate, propylene glycol, sorbitol (70%), petrolatum, sorbic acid, simethicone, and butylated hydroxytoluene.
- laser energy 12 is applied to the adipocyte tissue externally through the skin 14 of the patient, as illustrated in FIG. 1 .
- Sufficient laser energy is applied to release at least a portion of the intracellular fat 23 into the interstitial space 32 .
- the released intracellular fat is removed from the body through the body's normal systems, such as metabolic, lymphatic or excretory systems. The procedure may be repeated in one or more additional areas to remove additional fat there. In that event, additional laser energy would be applied externally to the new area. In this manner, specific areas of the body are contoured.
- fat leakage into the interstitial space is seen as early as 3-5 minutes of laser energy application. This leakage continues for treatments as long as about 12-15 minutes with no fat cell destruction.
- the preferred treatment is about 30 minutes of laser energy application, three times a week for about two weeks.
- the laser energy is preferably applied by a scanning laser.
- the laser energy can be applied by a therapist freely moving a non-scanning laser energy source over the area desired for improved contouring or fat reduction.
- the laser energy can be emitted from a stationary source, such as an arm that emits laser energy which is attached to a wall or a stand.
- FIG. 2 illustrates adipose tissue comprising normal fat cells 21 wherein the cell membrane 22 is filled with intracellular fat 23 .
- the cell membrane 22 Upon sufficient doses of low-level laser energy, the cell membrane 22 is momentarily disrupted, releasing the intracellular fat 23 .
- FIG. 3 illustrates pores 31 in the cellular membrane 22 which have released intracellular fat 23 into the interstitial space 32 .
- the pores 31 close and the cell membrane 22 returns to contiguity.
- the fat cell is not destroyed, provided the duration of laser treatment is appropriate. For a 635 nm laser of less than 1 W, treatments of less than about 12 minutes do not destroy cells.
- niacin Once released into the interstitial space, the fat is metabolized by normal processes within the body.
- the administration of a therapeutic amount of niacin increases the amount of fat that is metabolized.
- the mechanism is believed to be increased oxidation of the fatty acids and triglycerides by biochemically active forms of niacin such as nicotinamide adenine dinucleotide (NAD+).
- NAD+ nicotinamide adenine dinucleotide
- one of the steps in the breakdown of fatty acids and glycolysis is the use of NAD+ to produce ATP.
- niacin is also a vasodilator. With the relaxation and dilation of nearby blood vessels, it is possible for the fatty acids and triglycerides to be absorbed into the blood stream rather than reabsorbed by the adipocyte cell.
- the laser energy applied is low level, that is, the treatment has a dose rate that causes no immediate detectable temperature rise of the treated tissue and no macroscopically visible changes in tissue structure.
- the laser energy penetrates the skin and is specific to the depth of the desired zone of fat to be treated. Consequently, the treated and surrounding tissue is not heated and is not damaged.
- Preferably the laser light is visible to the human eye so that the area of application is easily determined.
- a laser device that provides this low-level energy is known in the art as a cold laser, such as the inventions described in U.S. Pat. Nos. 6,013,096 issued to Tucek and 6,746,473, issued to Tucek and Shanks.
- the preferred laser is a semiconductor diodes emitting laser light at 625 nm.
- lasers known in the art for use in low-level laser therapy include Helium-Neon lasers having a 632 nm wavelength and semiconductor diode lasers with a broad range of wavelengths between 405-1500 nm. Diode lasers at 633 nm, 670 nm and 1064 nm (infrared) have been shown to work with varying degrees of success.
- the laser device may have one or more laser energy sources. Different therapy regimens require diodes of different wattages. The preferred laser diodes use less than one watt of power each to simultaneously facilitate liposuction, treat post-operative inflammation, and post-operative pain. Diodes of various other wattages may also be employed to achieve the desired laser energy for the given regimen. Low-level lasers are available commercially.
- the dosage of laser energy required to achieve release of the intracellular fat into the interstitial space will vary depending on the thickness of the patient's skin, thickness of fatty tissue, and other biological factors peculiar to each patient.
- the following preferred embodiment is illustrative.
- a patient is administered 500 mg of niacin orally by tablet on a first day. The next day, the patient is administered 600 mg of niacin orally by tablet.
- the patient is treated with a 635 nm semiconductor diode laser with maximum power of 10 mW to apply laser light to a patient's pads of fat located in the area near his waist, around his side and back, commonly referred to as “love handles.”
- the laser energy is applied for 30 minutes using a scanning laser.
- the third day the patient is administered 700 mg of niacin, 800 mg on the fourth day, 900 mg on the fifth day, 1000 mg on the sixth day, all orally by tablet.
- the patient is again treated for 30 minutes with a 635 nm semiconductor diode laser to the patient's love handles.
- the seventh day the patient is administered 1100 mg of niacin, 1200 mg on the eighth day, and 1300 mg on the ninth day.
- the patient is again treated for 30 minutes with a 635 nm semiconductor diode laser to the patient's love handles.
- the patient On the tenth day of niacin administration, the patient is administered 1400 mg of niacin and 1500 mg on the eleventh day through the 14th day.
- the patient is again treated for 30 minutes with a 635 nm semiconductor diode laser to the patient's love handles.
- the love handles are reduced, and the patient suffered no pain or bruising.
Abstract
The present invention is a non-invasive method for reducing fat or cellulite in a patient by administering a therapeutically effective amount of niacin and applying laser energy to targeted external regions of a patient's body. The present method helps create smooth contours.
Description
- This application is a continuation of co-pending U.S. patent application Ser. No. 11/522,136 filed Sep. 14, 2006, which is a continuation-in-part of co-pending U.S. patent application Ser. No. 11/053369 filed Feb. 7, 2005 which claims the benefit of co-pending U.S. Provisional Application No. 60/542,720 filed Feb. 6, 2004.
- This invention relates to a method for non-invasive, non-traumatic shaping and contouring of a human body by external means. In particular, this invention relates to administering niacin to a patient to enhance the effects of applying laser energy to targeted external regions of a patient's body to reduce fat by facilitating the removal of the intracellular fat from fat cells in the targeted areas.
- There is a great demand to be slimmer and have smoother contours. Many people resort to the cosmetic surgical procedure known as liposuction, wherein excess adipose tissue, also known as fat, is suctioned from the body of a patient. The typical purpose of the liposuction procedure is to leave the patient thinner, with aesthetically more appealing body contours. For example, liposuction is often performed on patients to remove excess fat in the abdominal, buttock, thigh, breast and arm regions of the body.
- Adipose tissue is made of adipocytes, or fat cells, which are enclosed membranes filled with globules of triglycerides. In normal fat the fat cells have regular contours and form into grapelike clusters. The intracellular fat is relatively fluid and, if the membrane is pierced, will flow out of the cell into the interstitial space. The interstitial space includes nerves, blood vessels, lymphatics and collagen fibers, among other substances.
- Liposuction is performed by inserting a narrow tube, or cannula, through a tiny incision in the skin into the subcutaneous fatty tissue. The cannula is repeatedly pushed then pulled through the fat layer, separating and puncturing the fat cells and suctioning them out. Suction action through the cannula is provided by a vacuum pump or a large syringe. The procedure carries with it some risks and side effects. Due to the physical damage induced, the procedure can damage nerves, lymphatics and vasculature in the surrounding area, often resulting in significant loss of blood as the blood is vacuumed out with the fat and the formation of seroma due to damaged lymphatic channels. In addition, the post-procedure recovery period is long and often accompanied by a great deal of inflammation, bruising and concomitant pain.
- Since the liposuction technique was first developed there have been many improvements to the technique, with the goal of making the surgery less dangerous for the patient, as well as reducing the negative aspects of the post-operative recovery period. For example, in the tumescent technique known in prior art, a saline solution containing very dilute amounts of at least an anesthetic and a vasoconstrictor is injected subcutaneously into the area to be suctioned. The anesthetic reduces operative and post-operative pain and the vasoconstrictor helps reduce blood loss. Cannulas have been improved by enabling the cannula to emit laser light and ultrasound energy directly onto the fat cells. This internal application of energy melts the cell wall, releasing the intracellular fat, thereby making the fatty tissue less viscous and more easily suctioned up through the narrow cannula. These procedures suffer the disadvantage of still having to physically stab the cannula repeatedly in the fat layer as well as essentially melting the adipose tissue, resulting in undesirable levels of bruising, inflammation, pain, blood loss, and seroma formation. Recovery time is significant.
- In U.S. Pat. No. 6,605,079, issued to one of the inventors of this method and incorporated herein, a less-destructive method is disclosed that uses low energy laser therapy in conjunction with suction of the fat cells. Low level laser therapy (LLLT) has been used increasingly in the treatment of a broad range of conditions such as treatment and repair of injured muscles and tendons. LLLT has improved wound healing, reduced edema, and relieved pain of various etiologies. LLLT has been used successfully post-operative to liposuction to reduce inflammation and pain. While a significant improvement over prior art, it is still invasive and carries with it the corresponding pain and risks.
- Non-invasive methods of fat reduction are preferred over invasive methods to minimize trauma to the patient, reduce the risk of infection, and speed up recovery time, among other reasons. To that end, topical agents have long been known which claim to reduce cellulite or at least the appearance of cellulite. Cellulite is a condition that gives the skin a rippled, dimpled appearance. The effect of these agents on cellulite is somewhat dubious, and these agents are not known to actually reduce fat. Some of the topical agents are used in combination with massage or radiation of the affected areas.
- To avoid invasive procedures, electromagnetic energy, such as microwave, ultrasound or radio frequency radiation, has also been used to reduce fat. In U.S. Pat. No. 5,507,790 issued to Weiss, a method is described in which a medicament is applied to a patient's skin where fat removal is desired and focused electromagnetic energy is applied to the same work site to heat the fatty tissue and increase fat lipolysis. In U.S. Pat. No. 5,143,063, Fellner takes this method even farther, applying sufficient electromagnetic radiation to destroy the fat cells. Yet another method is to inject an intumescing solution below the skin and apply electromagnetic energy externally to the body. These procedures are disadvantageous in that they utilize such high energy sources that they excessively heat the surrounding tissue, which can result in damage to the tissue and pain. Again, recovery time is significant.
- Other external applications of certain types of destructive energy is known in the art. U.S. Pat. No. 6,645,162 issued to Friedman, et al. discloses the superposition of ultrasound waves from two or more sources to create a wave having high intensity localized at the adipose tissue to be treated. With this method, fat cells are sonically disintegrated, allowing the body to dispose of the fat that has been freed. In addition to destruction of cells, another difficulty with this method is accurately obtaining the desired focal zone under the skin.
- It is desirable to remove fat with less damage to the fatty tissue, less blood loss, less post-operative bruising, inflammation, and pain than existing methods. Therefore, an object of this invention is to provide a non-invasive method of reducing fat. Another object of this invention is to provide a non-invasive method of reducing cellulite. Another object is to provide a non-invasive method of reducing fat that does not destroy the fat cells, or damage surrounding tissue or structures. Another object is reduce fat using niacin to enhance the effects of low-level laser therapy. It is another object to eliminate the need for recovery time.
- The present invention is a non-invasive method for reducing fat or cellulite in a patient by administering a therapeutically effective amount of niacin and applying laser energy to targeted external regions of a patient's body. The present method helps create smooth contours.
-
FIG. 1 is a schematic illustration of application of low-level laser radiation. -
FIG. 2 is a schematic illustration of normal fat cells. -
FIG. 3 is schematic illustration of fat cells after externally-applied low-level laser radiation. - The present invention combines niacin and low-level laser therapy to reduce fat in a patient and contour the body. Niacin is a water-soluble vitamin necessary for many aspects of health, growth, and reproduction. It is part of the vitamin B complex, and is also known as nicotinic acid or vitamin B-3. Niacin assists in the functioning of the digestive system, skin, and nerves. It is also important for the conversion of food to energy. Niacin is found in dairy products, poultry, fish, lean meats, nuts, and eggs. Legumes and enriched breads and cereals also supply some niacin.
- Niacin can be administered orally, topically, sublingually, nasally, intravenously or otherwise parenterally. As used herein, a therapeutic amount of niacin is the amount that increases the amount of fat metabolized by the patient's body. For example, the therapeutically effective amount of niacin administered orally can be about 500 mg or more than about 15 mg. The therapeutically effective amount of niacin administered topically can be about 7 g. In the preferred embodiment, niacin is administered in a therapeutic amount orally, by tablet or liquid. Niacin is administered to the patient over a span of about two weeks. About 500 mg is taken per day during the first day and increased until the patient is taking about 1500 mg per day on the eleventh day. Preferably the patient is given 500 mg the first day in a single dose, and 100 mg is added each day to the dose until the patient is taking 1500 mg per dose. While most patients can tolerate relatively high doses of niacin, for example up to 3 grams a day, even smaller doses than those of the preferred embodiment can be associated with skin flushing and itching. It is desirable to keep the dose low enough to prevent the patient from being uncomfortable. The amount of niacin that is well-tolerated will differ for each patient. Similarly, the effect of the niacin and laser therapy will differ for each patient. The total amount of niacin administered, dose, timing and length of administration will vary for each patient, depending on the patient's tolerance, weight, body fat mass, and lean body mass, among other factors.
- In another embodiment, niacin is administered topically to the patient in a therapeutic amount over a span of about two weeks. In a preferred embodiment, 7 grams of niacin is applied daily to the desired area. The niacin is carried in a lotion. For example, a 20% niacin formulation is composed of Nia-112, commonly known as dodecyl nicotinate and nicotinic acid dodecyl ester included in a mixture of conventional ingredients found in a water- or lipid-soluble base. One such lotion comprises a nonionic surfactant such as Brij 58 (polyoxyethylene 20 cetyl ether), cetostearyl alcohol, glyceryl monostearate, polyethylene glycol 400 monostearate, propylene glycol, sorbitol (70%), petrolatum, sorbic acid, simethicone, and butylated hydroxytoluene. As with the oral administration, the amount of niacin that is well-tolerated will differ for each patient. Similarly, the effect of the niacin and laser therapy will differ for each patient. The total amount of niacin administered, dose, timing and length of administration will vary for each patient, depending on the patient's tolerance, weight, body fat mass, and lean body mass, among other factors.
- Upon the administration of niacin,
laser energy 12 is applied to the adipocyte tissue externally through theskin 14 of the patient, as illustrated inFIG. 1 . Sufficient laser energy is applied to release at least a portion of theintracellular fat 23 into theinterstitial space 32. The released intracellular fat is removed from the body through the body's normal systems, such as metabolic, lymphatic or excretory systems. The procedure may be repeated in one or more additional areas to remove additional fat there. In that event, additional laser energy would be applied externally to the new area. In this manner, specific areas of the body are contoured. - Typically, fat leakage into the interstitial space is seen as early as 3-5 minutes of laser energy application. This leakage continues for treatments as long as about 12-15 minutes with no fat cell destruction. The preferred treatment is about 30 minutes of laser energy application, three times a week for about two weeks. The laser energy is preferably applied by a scanning laser. Alternatively, the laser energy can be applied by a therapist freely moving a non-scanning laser energy source over the area desired for improved contouring or fat reduction. Alternatively, the laser energy can be emitted from a stationary source, such as an arm that emits laser energy which is attached to a wall or a stand.
- The mechanism involved in releasing the intracellular fat from the cells is believed to be the formation of a transitory pore in the cell membrane.
FIG. 2 illustrates adipose tissue comprisingnormal fat cells 21 wherein thecell membrane 22 is filled withintracellular fat 23. Upon sufficient doses of low-level laser energy, thecell membrane 22 is momentarily disrupted, releasing theintracellular fat 23. SeeFIG. 3 , which illustratespores 31 in thecellular membrane 22 which have releasedintracellular fat 23 into theinterstitial space 32. Upon cessation of the energy application, thepores 31 close and thecell membrane 22 returns to contiguity. The fat cell is not destroyed, provided the duration of laser treatment is appropriate. For a 635 nm laser of less than 1 W, treatments of less than about 12 minutes do not destroy cells. - Once released into the interstitial space, the fat is metabolized by normal processes within the body. The administration of a therapeutic amount of niacin increases the amount of fat that is metabolized. The mechanism is believed to be increased oxidation of the fatty acids and triglycerides by biochemically active forms of niacin such as nicotinamide adenine dinucleotide (NAD+). As known in the art, one of the steps in the breakdown of fatty acids and glycolysis is the use of NAD+ to produce ATP. In addition to niacin's ability to oxidize molecules, niacin is also a vasodilator. With the relaxation and dilation of nearby blood vessels, it is possible for the fatty acids and triglycerides to be absorbed into the blood stream rather than reabsorbed by the adipocyte cell.
- The laser energy applied is low level, that is, the treatment has a dose rate that causes no immediate detectable temperature rise of the treated tissue and no macroscopically visible changes in tissue structure. The laser energy penetrates the skin and is specific to the depth of the desired zone of fat to be treated. Consequently, the treated and surrounding tissue is not heated and is not damaged. Preferably the laser light is visible to the human eye so that the area of application is easily determined. A laser device that provides this low-level energy is known in the art as a cold laser, such as the inventions described in U.S. Pat. Nos. 6,013,096 issued to Tucek and 6,746,473, issued to Tucek and Shanks. The preferred laser is a semiconductor diodes emitting laser light at 625 nm. Other lasers known in the art for use in low-level laser therapy include Helium-Neon lasers having a 632 nm wavelength and semiconductor diode lasers with a broad range of wavelengths between 405-1500 nm. Diode lasers at 633 nm, 670 nm and 1064 nm (infrared) have been shown to work with varying degrees of success. The laser device may have one or more laser energy sources. Different therapy regimens require diodes of different wattages. The preferred laser diodes use less than one watt of power each to simultaneously facilitate liposuction, treat post-operative inflammation, and post-operative pain. Diodes of various other wattages may also be employed to achieve the desired laser energy for the given regimen. Low-level lasers are available commercially.
- The dosage of laser energy required to achieve release of the intracellular fat into the interstitial space will vary depending on the thickness of the patient's skin, thickness of fatty tissue, and other biological factors peculiar to each patient. The following preferred embodiment is illustrative.
- A patient is administered 500 mg of niacin orally by tablet on a first day. The next day, the patient is administered 600 mg of niacin orally by tablet. The patient is treated with a 635 nm semiconductor diode laser with maximum power of 10 mW to apply laser light to a patient's pads of fat located in the area near his waist, around his side and back, commonly referred to as “love handles.” The laser energy is applied for 30 minutes using a scanning laser.
- The third day the patient is administered 700 mg of niacin, 800 mg on the fourth day, 900 mg on the fifth day, 1000 mg on the sixth day, all orally by tablet. The patient is again treated for 30 minutes with a 635 nm semiconductor diode laser to the patient's love handles.
- The seventh day the patient is administered 1100 mg of niacin, 1200 mg on the eighth day, and 1300 mg on the ninth day. The patient is again treated for 30 minutes with a 635 nm semiconductor diode laser to the patient's love handles.
- On the tenth day of niacin administration, the patient is administered 1400 mg of niacin and 1500 mg on the eleventh day through the 14th day. The patient is again treated for 30 minutes with a 635 nm semiconductor diode laser to the patient's love handles. The love handles are reduced, and the patient suffered no pain or bruising.
- While there has been illustrated and described what is at present considered to be a preferred embodiment of the present invention, it will be understood by those skilled in the art that various changes and modifications may be made, and equivalents may be substituted for elements thereof without departing from the true scope of the invention. Therefore, it is intended that this invention not be limited to the particular embodiment disclosed as the best mode contemplated for carrying out the invention, but that the invention will include all embodiments falling within the scope of the appended claims.
Claims (13)
1. A method for reducing fat in a patient comprising:
a) orally administering to the patient a therapeutically effective amount of niacin; and
b) applying laser energy to the tissue of the patient with no temperature rise of the lasered and surrounding tissue.
2. The method of claim 1 wherein the therapeutically effective amount of niacin is about 500 mg.
3. The method of claim 1 wherein the therapeutically effective amount of niacin is more than about 15 mg.
4. The method of claim 1 wherein applied laser energy is about 635 nm.
5. A method for reducing fat in a patient comprising:
a. topically administering to the patient a therapeutically effective amount of niacin; and
b. applying laser energy to the tissue of the patient with no temperature rise of the lasered and surrounding tissue.
6. The method of claim 5 wherein the therapeutically effective amount of niacin is more than about 7 mg.
7. The method of claim 5 wherein applied laser energy is about 635 nm.
8. In a patient having fat that comprises fat cells having intracellular fatty acids and triglycerides and interstitial space between the fat cells, a method of reducing fat comprising:
a. taking in a therapeutically effective amount of niacin;
b. receiving an application of laser energy in an amount that causes no detectable temperature rise of the treated tissue;
c. releasing at least a portion of the intracellular fat into the interstitial space; and
d. absorbing fatty acids and triglycerides into the patient's blood stream.
9. The method of claim 8 wherein taking in further comprises the patient digesting niacin administered orally.
10. The method of claim 9 wherein about 500 mg of niacin is taken in the first day and the niacin amount is increased until the patient takes in about 1500 mg on the eleventh day.
11. The method of claim 8 wherein taking in further comprises the patient absorbing niacin administered topically.
12. The method of claim 11 wherein the patient absorbs more than about 7 mg of niacin.
13. The method of claim 8 wherein applied laser energy is about 635 nm.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/198,491 US20110295187A1 (en) | 2004-02-06 | 2011-08-04 | Fat Reduction Using External Laser Radiation and Niacin |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54272004P | 2004-02-06 | 2004-02-06 | |
US11/053,369 US8932338B2 (en) | 2004-02-06 | 2005-02-07 | Noninvasive method for site-specific fat reduction |
US11/522,136 US7993382B2 (en) | 2004-02-06 | 2006-09-14 | Fat reduction using external laser radiation and niacin |
US13/198,491 US20110295187A1 (en) | 2004-02-06 | 2011-08-04 | Fat Reduction Using External Laser Radiation and Niacin |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/522,166 Continuation US7663257B2 (en) | 2003-10-09 | 2006-09-15 | Self-powered miniature liquid treatment system with configurable hydropower generator |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110295187A1 true US20110295187A1 (en) | 2011-12-01 |
Family
ID=46326087
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/522,136 Expired - Fee Related US7993382B2 (en) | 2004-02-06 | 2006-09-14 | Fat reduction using external laser radiation and niacin |
US13/198,491 Abandoned US20110295187A1 (en) | 2004-02-06 | 2011-08-04 | Fat Reduction Using External Laser Radiation and Niacin |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/522,136 Expired - Fee Related US7993382B2 (en) | 2004-02-06 | 2006-09-14 | Fat reduction using external laser radiation and niacin |
Country Status (1)
Country | Link |
---|---|
US (2) | US7993382B2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120310235A1 (en) * | 2006-06-14 | 2012-12-06 | Paithankar Dilip Y | Treatment of skin by spatial modulation of thermal heating |
US20130123765A1 (en) * | 2011-11-16 | 2013-05-16 | Btl Holdings Limited | Methods and systems for subcutaneous treatments |
US20130123764A1 (en) * | 2011-11-16 | 2013-05-16 | Btl Holdings Limited | Methods and systems for subcutaneous treatments |
US9446258B1 (en) | 2015-03-04 | 2016-09-20 | Btl Holdings Limited | Device and method for contactless skin treatment |
US9468774B2 (en) | 2011-11-16 | 2016-10-18 | Btl Holdings Limited | Methods and systems for skin treatment |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7993382B2 (en) * | 2004-02-06 | 2011-08-09 | Erchonia Corporation | Fat reduction using external laser radiation and niacin |
US9498641B2 (en) | 2012-03-05 | 2016-11-22 | Blue Water Innovations, Llc | Fat reducing device and method utilizing optical emitters |
EP3065823B1 (en) | 2013-11-06 | 2020-09-09 | Terry Ward | Cellulite and fat reducing device and method utilizing optical emitters |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020123743A1 (en) * | 2001-03-02 | 2002-09-05 | Shanks Steven C. | Method for performing lipoplasty using external laser radiation |
US20020193831A1 (en) * | 2001-04-26 | 2002-12-19 | Smith Edward Dewey | Method and apparatus for the treatment of cosmetic skin conditions |
US20030069618A1 (en) * | 2001-04-26 | 2003-04-10 | Smith Edward Dewey | Method, kit and device for the treatment of cosmetic skin conditions |
US6676655B2 (en) * | 1998-11-30 | 2004-01-13 | Light Bioscience L.L.C. | Low intensity light therapy for the manipulation of fibroblast, and fibroblast-derived mammalian cells and collagen |
US20040181210A1 (en) * | 2003-03-10 | 2004-09-16 | Shellman Jeremy J. | Method for administering phototherapy as a cellulite firming treatment |
US20050203593A1 (en) * | 2003-10-24 | 2005-09-15 | Shanks Steven C. | Method for dermatology therapies in combination with low level laser treatments |
US20050203594A1 (en) * | 2004-02-06 | 2005-09-15 | Susan Lim | Noninvasive method for site-specific fat reduction |
US20070100402A1 (en) * | 2004-02-06 | 2007-05-03 | Erchonia Medical, Inc. | Fat reduction using external laser radiation and niacin |
US20080125837A1 (en) * | 2004-02-06 | 2008-05-29 | Therapy Products, Inc. | Noninvasive method for site-specific fat reduction with catalyst |
US20110087312A1 (en) * | 2001-03-02 | 2011-04-14 | Erchonia Corporatin | Method for Treatment of Diabetes and Prediabetes with Low-Level Laser Therapy |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5143063A (en) | 1988-02-09 | 1992-09-01 | Fellner Donald G | Method of removing adipose tissue from the body |
JP3168207B2 (en) | 1990-08-22 | 2001-05-21 | ヴィスクス・インコーポレイテッド | Surgical laser beam scanning device |
WO1993021993A1 (en) | 1992-04-24 | 1993-11-11 | Kim Robin Segal | Low level laser for soft tissue treatment |
US5507790A (en) | 1994-03-21 | 1996-04-16 | Weiss; William V. | Method of non-invasive reduction of human site-specific subcutaneous fat tissue deposits by accelerated lipolysis metabolism |
US5743902A (en) | 1995-01-23 | 1998-04-28 | Coherent, Inc. | Hand-held laser scanner |
US5860968A (en) | 1995-11-03 | 1999-01-19 | Luxar Corporation | Laser scanning method and apparatus |
US5725482A (en) | 1996-02-09 | 1998-03-10 | Bishop; Richard P. | Method for applying high-intensity ultrasonic waves to a target volume within a human or animal body |
US6013096A (en) | 1996-11-22 | 2000-01-11 | Tucek; Kevin B. | Hand-held laser light generator device |
US6517532B1 (en) | 1997-05-15 | 2003-02-11 | Palomar Medical Technologies, Inc. | Light energy delivery head |
AU8149198A (en) | 1997-06-17 | 1999-01-04 | Cool Laser Optics, Inc. | Method and apparatus for temperature control of biologic tissue with simultaneous irradiation |
DE19725877B4 (en) | 1997-06-18 | 2004-02-05 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Application device for removing biological tissue |
US6235016B1 (en) | 1999-03-16 | 2001-05-22 | Bob W. Stewart | Method of reducing sebum production by application of pulsed light |
DE29916584U1 (en) | 1999-09-21 | 2000-05-04 | Laser & Med Tech Gmbh | Swash optics for high-performance light sources |
BR0115093A (en) | 2000-11-03 | 2004-06-15 | Elliot Lach | System for treating a condition of a patient and method of using a condition treatment system |
US6645162B2 (en) | 2000-12-27 | 2003-11-11 | Insightec - Txsonics Ltd. | Systems and methods for ultrasound assisted lipolysis |
US6746473B2 (en) | 2001-03-02 | 2004-06-08 | Erchonia Patent Holdings, Llc | Therapeutic laser device |
ITFI20010133A1 (en) | 2001-07-13 | 2003-01-13 | El En Spa | ANTI-CELLULITE EQUIPMENT WITH COMPOSITE TECHNIQUES |
US20040147984A1 (en) | 2001-11-29 | 2004-07-29 | Palomar Medical Technologies, Inc. | Methods and apparatus for delivering low power optical treatments |
US20040191278A1 (en) * | 2003-03-31 | 2004-09-30 | Christensen Flemming Kjaergaar | Topical agent for application to the skin prior to luminous treatment |
US9149322B2 (en) | 2003-03-31 | 2015-10-06 | Edward Wells Knowlton | Method for treatment of tissue |
US7914523B2 (en) | 2004-02-06 | 2011-03-29 | Clinique Dr Daniel Barolet Inc. | Method for the treatment of mammalian tissues |
-
2006
- 2006-09-14 US US11/522,136 patent/US7993382B2/en not_active Expired - Fee Related
-
2011
- 2011-08-04 US US13/198,491 patent/US20110295187A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6676655B2 (en) * | 1998-11-30 | 2004-01-13 | Light Bioscience L.L.C. | Low intensity light therapy for the manipulation of fibroblast, and fibroblast-derived mammalian cells and collagen |
US20020123743A1 (en) * | 2001-03-02 | 2002-09-05 | Shanks Steven C. | Method for performing lipoplasty using external laser radiation |
US20110087312A1 (en) * | 2001-03-02 | 2011-04-14 | Erchonia Corporatin | Method for Treatment of Diabetes and Prediabetes with Low-Level Laser Therapy |
US20020193831A1 (en) * | 2001-04-26 | 2002-12-19 | Smith Edward Dewey | Method and apparatus for the treatment of cosmetic skin conditions |
US20030069618A1 (en) * | 2001-04-26 | 2003-04-10 | Smith Edward Dewey | Method, kit and device for the treatment of cosmetic skin conditions |
US20040181210A1 (en) * | 2003-03-10 | 2004-09-16 | Shellman Jeremy J. | Method for administering phototherapy as a cellulite firming treatment |
US20050203593A1 (en) * | 2003-10-24 | 2005-09-15 | Shanks Steven C. | Method for dermatology therapies in combination with low level laser treatments |
US20050203594A1 (en) * | 2004-02-06 | 2005-09-15 | Susan Lim | Noninvasive method for site-specific fat reduction |
US20070100402A1 (en) * | 2004-02-06 | 2007-05-03 | Erchonia Medical, Inc. | Fat reduction using external laser radiation and niacin |
US20080125837A1 (en) * | 2004-02-06 | 2008-05-29 | Therapy Products, Inc. | Noninvasive method for site-specific fat reduction with catalyst |
US7993382B2 (en) * | 2004-02-06 | 2011-08-09 | Erchonia Corporation | Fat reduction using external laser radiation and niacin |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120310235A1 (en) * | 2006-06-14 | 2012-12-06 | Paithankar Dilip Y | Treatment of skin by spatial modulation of thermal heating |
US9486285B2 (en) * | 2006-06-14 | 2016-11-08 | Candela Corporation | Treatment of skin by spatial modulation of thermal heating |
US20130123765A1 (en) * | 2011-11-16 | 2013-05-16 | Btl Holdings Limited | Methods and systems for subcutaneous treatments |
US20130123764A1 (en) * | 2011-11-16 | 2013-05-16 | Btl Holdings Limited | Methods and systems for subcutaneous treatments |
US8548599B2 (en) * | 2011-11-16 | 2013-10-01 | Btl Holdings Limited | Methods and systems for subcutaneous treatments |
US9468774B2 (en) | 2011-11-16 | 2016-10-18 | Btl Holdings Limited | Methods and systems for skin treatment |
US9867996B2 (en) | 2011-11-16 | 2018-01-16 | Btl Holdings Limited | Methods and systems for skin treatment |
US9446258B1 (en) | 2015-03-04 | 2016-09-20 | Btl Holdings Limited | Device and method for contactless skin treatment |
US9962553B2 (en) | 2015-03-04 | 2018-05-08 | Btl Holdings Limited | Device and method for contactless skin treatment |
Also Published As
Publication number | Publication date |
---|---|
US20070100402A1 (en) | 2007-05-03 |
US7993382B2 (en) | 2011-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8932338B2 (en) | Noninvasive method for site-specific fat reduction | |
US20110295187A1 (en) | Fat Reduction Using External Laser Radiation and Niacin | |
US9149650B2 (en) | Non-invasive method for slimming a human body using laser energy of wavelengths shorter than 632 nm | |
US10493293B2 (en) | Aesthetic method of biological structure treatment by magnetic field | |
US10688310B2 (en) | Aesthetic method of biological structure treatment by magnetic field | |
US10569094B2 (en) | Aesthetic method of biological structure treatment by magnetic field | |
Fabi et al. | Hand rejuvenation: a review and our experience | |
US10549110B1 (en) | Aesthetic method of biological structure treatment by magnetic field | |
US6605079B2 (en) | Method for performing lipoplasty using external laser radiation | |
US20170106201A1 (en) | Combination of magnetic and electromagnetic treatment method | |
US20160066994A1 (en) | Non-Invasive Method for Slimming a Human Body Using Two Wavelngths of Laser Energy Concurrently | |
US20090177123A1 (en) | Methods for treating inflammatory disorders | |
Goldman et al. | Laser-assisted liposuction | |
Mann et al. | New advances in liposuction technology | |
Bissell | Therapeutic modalities in hand surgery | |
Nossair et al. | Advanced protocol of shock wave therapy for diabetic foot ulcer | |
Annie Liu et al. | Treatment of sebaceous hyperplasia by laser modalities: a review of the literature and presentation of our experience with erbium-doped yttrium aluminium garnet (Er: YAG) | |
Gaspar | Case report: combined Er: YAG and Nd: YAG laser treatment for non-invasive body contouring | |
US20080125837A1 (en) | Noninvasive method for site-specific fat reduction with catalyst | |
Salati | Cellulite: A review of the current treatment modalities | |
Nestor et al. | Lasers and aesthetic devices: skin resurfacing, tattoo removal, and body contouring | |
US6553254B1 (en) | Combination of non-living-source physical energy and living-source chemical energy to maximize the salvage of ATP | |
KR102335712B1 (en) | Composition for lipolysis and injection apparatus thereof | |
Majid | Cutaneous warts treatment modalities | |
Gold et al. | Nonsurgical fat reduction: Cryolipolysis, RF skin tightening, HIFEM, and injectable lipolysis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ERCHONIA CORPORATION, TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHANKS, STEVEN C.;MALONEY, RYAN;SIGNING DATES FROM 20111221 TO 20111227;REEL/FRAME:027496/0456 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |